

Invited Speakers

Frederic Amant (Belgium)
Sarah Blagden (UK)
Tom Bourne (UK)
Elisabeth Epstein (Sweden)
Daniela Fischerova (Czech Republic)
Christina Fotopoulou (UK and Germany)
Dorella Franchi (Italy)
Hani Gabra (UK)
Stefano Guerriero (Italy)
Jeroen Kaijser (Belgium)
Francesco Leone (Italy)
Usha Menon (UK)
Luca Savelli (Italy)
Ahmad Sayasneh (UK)

Antonia Testa (Italy)
Isabelle Thomassin-Nagarra (France)
Dirk Timmerman (Belgium)
Lil Valentin (Sweden)
Ben Van Calster (Belgium)
Vincent Vandecaveye (Belgium)
Thierry Van den Bosch (Belgium)
Toon Van Gorp (The Netherlands)
Caroline Van Holsbeke (Belgium)
Kirsten Van Hoorde (Belgium)
Ignace Vergote (Belgium)
Laure Wynants (Belgium)
Gianfranco Zannoni (Italy)

Parking

Friday & Saturday : follow the arrows to 'Villa' (for free).

Website

<http://www.iotagroup.org/>

Local Organizing Committee

T. Bourne
A. Deblander
B. De Moor
J. Deprest
S. Housmans
J. Kaijser
A. Pexsters
D. Timmerman
B. Van Calster
C. Van Holsbeke
S. Van Huffel
I. Vergote

Venue

University Hospitals Leuven
Campus Gasthuisberg
Onderwijs en Navorsing 1 & 2
Herestraat 49
3000 Leuven

Accreditation

Accreditation has been requested
(Ethics & Economy)

Congress secretariat

Mrs. Diane Wolput
tel. +32 16 34 42 02
fax. +32 16 34 42 05
diane.wolput@uzleuven.be

Mrs. Marleen Craessaerts
tel. +32 16 34 36 06
fax +32 16 34 38 36
marleen.craessaerts@uzleuven.be

Mrs. Linda Simons
tel. +32 16 34 42 16
fax +32 16 34 42 05
linda.simons@uzleuven.be

University Hospitals Leuven
Campus Gasthuisberg
Herestraat 49
3000 Leuven - Belgium

Educational course approved by



Concilium van Hoogleraren
Gynaecologie en Verloskunde



KU LEUVEN



Supported by



GE Healthcare



IOTA 2015
International Ovarian Tumor Analysis
Second International IOTA Congress

**How to classify
and manage
ovarian
tumors ?**

April 17 - 18, 2015
Leuven, Belgium

University Hospitals Leuven
Onderwijs & Navorsing
(Education and Research)



Dear Colleague

We invite you to participate to the Second International Ovarian Tumor Analysis (IOTA) Congress which will be organized in Leuven, Belgium on April 17-18 2015.

Over the last 15 years the group has standardized the approach to the ultrasound description of ovarian pathology and redefined the characterisation of both malignant and benign adnexal tumors. There are now over 50 centers participating in IOTA studies in 20 countries around the world.

The aim of the second international congress is to communicate what we have learnt from the study of over 10,000 adnexal masses. We will focus on education in gynecological ultrasonography and the management of ovarian pathology as well as the evaluation of cancer once it has been diagnosed. The international faculty includes experts from a range of fields including ultrasonography, gynecologic oncology, pathology and radiology.

At the end of the course participants should be familiar with all IOTA terms and definitions for ovarian tumors as well as practical clinical approaches to the evaluation and management of adnexal pathology. After successfully completing an MCQ test at the end of the congress official IOTA certificates will be available.

With its attractive central market square, Leuven is a very pleasant and lively medieval town. It hosts both the largest brewery in the world (AB Inbev) as well as the oldest university in the lower lands (KU Leuven, founded in 1425) with 40,000 students. Leuven has excellent transport links being only twenty minutes by train from Brussels Airport or from Brussels Midi station with prompt connections to Eurostar.

We look forward to meeting you in Leuven. With best regards,

Dirk Timmerman, Tom Bourne, Antonia Carla Testa, Lil Valentin
Ben Van Calster, Sabine Van Huffel, Ignace Vergote

DAY 1:
Friday, April 17, 2015

CHAIR: TOM BOURNE

08:00 – 09:15 Ovarian pathology: Meet the expert ‘round table’ sessions
1. Practical use of IOTA prediction apps in the clinic | Caroline van Holsbeke
2. How to look at 3D volumes in gynecology | Lil Valentin
3. How to describe endometrial and myometrial findings: nomenclature for endometrial and myometrial pathology | Thierry Van den Bosch
4. IOTA variables explained | Ahmad Sayasneh
5. When and how to perform Trucut biopsies in the context of ovarian tumor management | Daniela Fischerova
6. Understanding how to interpret diagnostic test results: statistics made very simple for clinicians | Laure Wynants and Kirsten Van Hoorde

09:15 – 09:45 Welcome and a summary of where the IOTA project currently stands | Dirk Timmerman

09:45 – 10:15 Why characterizing ovarian pathology matters | Ignace Vergote
10:15 – 10:45 Reviewing IOTA terminology, definitions and rules used to describe ovarian tumors | Lil Valentin

10.45 – 11:15 Coffee break

THE EVIDENCE BASE

11:15 – 11.45 What is the best test? Meta-analysis and systematic review of currently available evidence on the classification of ovarian pathology (RMI) | Jeroen Kaijser

11.45 – 12:15 Understanding test performance – what risk of ovarian cancer do we mean when women have a negative or positive test for the disease? How do tests perform in different centres? Do prediction models work even when variables are measured differently in different centres? | Ben Van Calster

12:15 – 12.30 Discussion

12.30 – 14:00 Lunch break

HOW IOTA MODELS PERFORM IN DIFFERENT CONTEXTS

14:00 – 14:30 The IOTA models – validation by the IOTA group and performance when validated elsewhere | Caroline Van Holsbeke

14:30 – 15:00 The UKTOCS and FOCSS trials - what have we learnt? | Usha Menon
15:00 – 15:30 What happens to conservatively managed masses classified as benign using IOTA rules and models? First data from the IOTA 5 trial with one year follow up. | Dirk Timmerman

15:30 – 16:00 Coffee break

TRANSLATIONAL MEDICINE

16:00 – 16:30 Current challenges in management of ovarian cancer: tumor heterogeneity, platinum resistance and predicting response. What does an oncologist want from diagnostic tests? | Hani Gabra

16:30 – 16:45 Posttranscriptional gene regulation in gynecological cancer | Sarah Blagden
16:45 – 17:00 HE4 and ROMA: do they add anything to the diagnosis of ovarian tumors – should we be using them? | Dorella Franchi

17:00 – 17:15 New tumor markers and proteomics | Toon Van Gorp
17:15 – 18:00 Discussion – what next? Is there potential to combine aspects of UKTOCS and IOTA to produce a better approach particularly in primary care? What trial should we be planning next? | Usha Menon, Dirk Timmerman, Hani Gabra, Tom Bourne, Sarah Blagden

18:00 – 19:00 Welcome reception: Foyer Biomedical Sciences offered by Roche

Speakers dinner after drinks

DAY 2:
Saturday, April 18, 2015

08:00-09:00 Meet the expert ‘round table’ sessions
1. Adnexal pathology that does not require intervention | Lil Valentin
2. Ultrasound in endometrial and cervical cancer | Elisabeth Epstein
3. How to use 3D and contrast to assess the uterus | Francesco Leone
4. Features of solid ovarian tumors | Antonia Testa
5. Looking for lymph nodes and when to biopsy | Daniela Fischerova
6. Assessment of deep endometriosis | Stefano Guerriero

RULES AND DESCRIPTORS

09:00-09:30 IOTA simple rules: what are they and can they be used to assign a risk of malignancy? | Dirk Timmerman

09:30-10:00 Using “descriptors” to characterize ovarian pathology | Tom Bourne
10:00-10:15 Recognising less common tumors: Dysgerminoma, Granulosa tumors, Brenner tumors, Fibromas, and Cystadenofibromas of the ovary | Lil Valentin

10:15-10:30 Just images to illustrate rules and descriptors | Elisabeth Epstein and Luca Savelli

10:30-11:00 Coffee break offered by Roche

DIFFERENTIATING CANCER TYPES AND PREGNANCY

11:00-11:30 Primary invasive, metastatic and borderline tumors: does an accurate pre-operative diagnosis impact on clinical management? | Christina Fotopoulou

11:30-12:00 The development of prediction models to discriminate between benign, borderline and malignant tumors: the ADNEX model | Ben Van Calster

12:00-12:30 The ADNEX model in clinical practice using decision support IOTA apps (Downloadable prior to meeting - see website) | Dorella Franchi, Luca Savelli, Dirk Timmerman
12:30-12:40 Discussion | Dirk Timmerman, Christina Fotopoulou, Ben Van Calster

12:40-14:00 Lunch break

OVARIAN CANCER STAGING, RECURRENCE AND PREGNANCY

14:00-14:20 Using ultrasound to stage ovarian malignancy | Daniela Fischerova
14:20-14:40 Full body MRI to stage ovarian cancer and role of PET CT in recurrent disease | Vincent Vandecaveye

14:40-15:00 Management of ovarian cysts and cancer in pregnancy | Frederic Amant
15:00-15:30 Discussion: How much does preoperative information about staging influence my decision when and if to operate or can we perform primary surgery with maximum effort on all patients? | Christina Fotopoulou and Ignace Vergote

15:30-16:00 Coffee break offered by Roche

16:00-16:30 Does MRI have a role in the classification of ovarian masses – is it useful for all masses or just difficult masses? The elements of the ADNEX MR scoring system | Isabelle Thomassin-Nagarra

16:30-17:00 Ultrasound to follow up women with invasive and borderline disease – how to detect recurrence and how to manage it. How to interpret changes associated with decidualisation in ovarian cysts. | Antonia Testa, Gianfranco Zannoni

17:00-17:40 IOTA MCQ just images quiz and exam | Lil Valentin, Antonia Testa
Sponsored by GE Healthcare

17:40-18:00 Closing remarks - Take home messages from IOTA research: how are you going to classify ovarian pathology and manage your patients? | Dirk Timmerman